ChemGenex raises $12.9m
Wednesday, 17 September, 2008
ChemGenex [ASX: CXS] has completed a $12.9 million capital raising through a share placement to institutional investors.
15.2 million shares were sold at $0.85 per share. Over half of these shares were purchased by existing major ChemGenex shareholders.
The company is also offering existing Australian shareholders the ability to participate on the same terms.
Existing major shareholders Alta Partners, GBS Venture Partners and Merck Snate committed $6.5 million.
The funds will be used for ChemGenex’s clinical trial program of its lead drug candidate, omacetaxine, for chronic myeloid leukaemia.
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
